Korlym lowers blood sugar, weight in people with Cushing’s, diabetes
Korlym (mifepristone) lowered the levels of hemoglobin A1c (HbA1c), which reflects the average amount of blood sugar over the past three months, in people with Cushing’s syndrome and treatment-resistant type 2 diabetes. That’s according to newly published data from the now-complete Phase 4 CATALYST (NCT05772169) clinical trial, which…